From Wikipedia, the free encyclopedia
Jump to: navigation, search
Legal status
Legal status
  • Investigational
Synonyms CDB-4124; 17β-(acetyloxy)-11β-[4-(dimethylamino)phenyl]-17α-(2-methoxyacetyl)estra-4,9-dien-3-one
CAS Number
PubChem CID
Chemical and physical data
Formula C31H39NO5
Molar mass 505.65 g/mol
3D model (Jmol)

Telapristone (INN), as telapristone acetate (proposed brand names Proellex, Progenta; former code name CDB-4124), is a synthetic, steroidal selective progesterone receptor modulator (SPRM) related to mifepristone which is under development by Repros Therapeutics for the treatment of breast cancer, endometriosis, and uterine fibroids.[1][2] It was originally developed by the National Institutes of Health (NIH), and, as of 2017, is in phase II clinical trials for the aforementioned indications.[1] In addition to its activity as an SPRM, the drug also has some antiglucocorticoid activity.[3]

See also[edit]


  1. ^ a b
  2. ^ Attardi BJ, Burgenson J, Hild SA, Reel JR (2004). "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone". J. Steroid Biochem. Mol. Biol. 88 (3): 277–88. PMID 15120421. doi:10.1016/j.jsbmb.2003.12.004. 
  3. ^ Whitaker LH, Williams AR, Critchley HO (2014). "Selective progesterone receptor modulators". Curr. Opin. Obstet. Gynecol. 26 (4): 237–42. PMID 24950125. doi:10.1097/GCO.0000000000000082. 

External links[edit]